VRX only worth $ 11

Discussion in 'Valeant Pharmaceuticals' started by anonymous, Sep 21, 2016 at 8:35 AM.

Tags: Add Tags

  1. anonymous

    anonymous Guest

    This was written by an idiot, unfortunately. He bought puts expiring in November, he said, and he keeps writing these basic Excel doomsday analyses.
     
  2. anonymous

    anonymous Guest

    Are you THAT stupid??? Valeant should just disappear. Your company went from $250 to $10 in less than one year lol. What an idiot! Here's another one for ya! Straight to Zero for you crooks!!

    https://www.thestreet.com/story/13570985/1/here-s-why-valeant-s-stock-is-heading-straight-to-zero.html?cm_ven_int=morej
     
  3. anonymous

    anonymous Guest

    That's from MAY.

    As far as this stock goes, that's ancient history.
     
  4. anonymous

    anonymous Guest

    The company is is no better shape than it was back in May.
     
  5. anonymous

    anonymous Guest

    This shit stock won't be worth $11 come December! Idiots!
     
  6. anonymous

    anonymous Guest

    It is getting closer to $ 11.00.
     
  7. anonymous

    anonymous Guest

    Almost there.
     
  8. anonymous

    anonymous Guest

    Down almost $5 premarket after earnings report (~25%).

    This pig is going to zero
     
  9. anonymous

    anonymous Guest

    Almost there
     
  10. anonymous

    anonymous Guest

    After PAPA is on CNBC today it will go under $10. Does not look good Bill A is dumping shares as I write this.
     
  11. anonymous

    anonymous Guest

    he did it for tax reasons. Nothing to see here.
     
  12. anonymous

    anonymous Guest

    Dead cat is bouncing, straight back to 250. Ain't going to floor at 11. Mark my words.
     
  13. anonymous

    anonymous Guest



    You are one stupid mother fucker!
     
  14. anonymous

    anonymous Guest

    Soooo close, yet so far. To all you naysayers predicting Chapter 11 or worse by the end of 2016. Well, the price may have slide a little more over the past 12 months, but we're still here kicking and screaming. Actually, don't you think this may be a good opportunity to put a toe in the water to see if it's still warm? It sounds like most of the bad news is behind it, so for 2017, it'll only get better since it can't get any worse. Papa said that all interest and principal payments due in 2017 are already paid down. So, we just need to focus on repairing our relationships with the doctors, pharmacies, government and insurance companies. Additionally, renew the tranches that are coming due soon and push it out 10 years. Lot of other pharmaceuticals have gone through some level of scrutiny in the past, so we're no different. They were able to come through it stronger and healthier than ever, so why can't we. When everybody hates us, that's when we should stock up.

    Happy New Year everyone!!
     
  15. anonymous

    anonymous Guest

    You are the problem!!! You are treating not hitting $11 or filing for Chapter 11 as a success. Hooray!!! Keep up the good work!!! God, I hope you are just a peon fanboy and not some senior executive.

    No. Valeant merely avoided going terminal this year. That is not a success. It's bad, just not that bad. Hold off on those bonuses until you have hit some actual positive milestones.
     
  16. anonymous

    anonymous Guest

    only an idiot VRX management member would celebrate dodging bankruptcy - with a 85% loss in market cap.
    future bright -
    when is pearson's trial?
     
  17. anonymous

    anonymous Guest

    a bright future for a pharma co involves having a pipeline of R&D products awaiting FDA approval.
    Valeant's future includes FDA denials and 483s at the production facilities, declining/aging product portfolio, profits via product increases alone, no more cash/credit to acquire growth through acquisition, and a disengaged staff that remain simply due to retention bonuses or because they cannot gain alternate employment.
    Cheers to 2017!
     
  18. anonymous

    anonymous Guest

    Wow, you guys think that this is the only company that has ever encounter some difficult challenges. We still generate a decent amount of revenues. Yeah, yeah, we have a lot of debt, but other companies have huge chunks as well. We just need some time to work through some of the rough patches that Pearson created. Schiller and Pearson are no longer here, so the bleeding has stopped. If we can get over the hump for the next few years, there will be more breathing room all around. The folks that are still working here are being patient, trying our best to keep the boat from sinking more. Chapter 11 aside, the company is still a viable entity and can probably survive it. Equity holders won't be happy, like those of you who currently bought in at over 100 and has held. I believe that you bashers have been hurt by this company in one form or another.

    Let go of your anger. It's not healthy. We are still clinging on to hope, since some of us still believe.
     
  19. anonymous

    anonymous Guest

    You can believe all you want to. The fact remains that this is the most toxic company to work for in our industry right now. Prepare to witness change coming in 2017. I'm talking about cuts in head count. Way to many sales reps to support the new biz model. Without Philidor the derm division is mediocre at best. Look at the numbers folks. Have you seen the attainment reports recently. Who's making money here anymore consistently. They are broke!!!

    The ride was way to short. We had about 14 months of great success, then it fell off the cliff.